Canine Degenerative Myelopathy: A Narrative Review of Aetiology, Clinical Signs, Diagnosis, and Therapy
Animals · 20.11.2026 · 16 (22) · 3688
DOI: 10.3390/ani16223688 ↗Kurz gefasst
Fachartikel in der Zeitschrift Animals, online erschienen am 20.11.2026. Verfasst von Marion Selina Brückler und 2 weiteren Autor:innen. Die Arbeit nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Canine degenerative myelopathy (DM) is a progressive, non-inflammatory neurodegenerative disease of the spinal cord that primarily affects middle-aged to older dogs and is closely related to human amyotrophic lateral sclerosis (ALS). This narrative review synthesises current knowledge on the aetiology, clinical presentation, diagnosis, and therapy of canine DM, based on a literature search conducted between October 2024 and May 2025 using Scopus, PubMed, and Google Scholar; included primary studies were graded according to the evidence classification system of the Cochrane Musculoskeletal Group. A mutation in the superoxide dismutase 1 (SOD1) gene, inherited in an autosomal recessive manner with incomplete penetrance (not all individuals with the disease-causing genotype develop clinical signs), has now been identified in dog populations across Europe, Asia, and South America. Definitive diagnosis still requires post-mortem histopathology of the spinal cord, whereas genetic testing—which identifies genetic risk but does not confirm clinical disease—combined with exclusion of differential diagnoses represents the most useful ante-mortem approach; advanced imaging, electromyography, and cerebrospinal fluid biomarkers contribute supportive but non-definitive information. Of the therapeutic options reviewed, physiotherapy is the only intervention with the strongest currently available evidence for prolonging survival time; quality-of-life benefits are reported clinically, but quality of life was not formally measured as a primary outcome in the main supporting study. Laser therapy, curcumin, cannabinoids, stem cell transplantation, and modulation of macrophage migration inhibitory factor show preliminary promise but remain investigational. Across nearly all areas, the evidence base is limited by small sample sizes and a scarcity of controlled trials, underlining the need for larger, well-controlled studies to improve early detection and treatment of this devastating disease. While the available evidence supports the clinical benefit of intensive physiotherapy, the majority of therapeutic interventions are supported by Silver- or Bronze-level evidence only, and controlled, randomised trials remain largely absent from the canine DM literature.
Zitieren
APA
Brückler, M. S., Reicher, B., & Mucha, M. (2026). Canine Degenerative Myelopathy: A Narrative Review of Aetiology, Clinical Signs, Diagnosis, and Therapy. Animals, 16(22), 3688. https://doi.org/10.3390/ani16223688
Vancouver
Brückler MS, Reicher B, Mucha M. Canine Degenerative Myelopathy: A Narrative Review of Aetiology, Clinical Signs, Diagnosis, and Therapy. Animals. 2026;16(22):3688. doi:10.3390/ani16223688
BibTeX
@article{Brckler2026,
author = {Brückler, Marion Selina and Reicher, Bianca and Mucha, Marion},
title = {Canine Degenerative Myelopathy: A Narrative Review of Aetiology, Clinical Signs, Diagnosis, and Therapy},
journal = {Animals},
year = {2026},
volume = {16},
number = {22},
pages = {3688},
doi = {10.3390/ani16223688}
}
EUVIMED